VistaGen Therapeutics Inc
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
Latest VTGN News